A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing ...

With travel scholarships available for the 2025 Coalition for Hemophilia B Symposium, columnist Jennifer Lynne encourages readers to attend.

The two-part Phase 1/2 trial — dubbed BeCoMe-9 (NCT06611436) — was designed to assess the safety and clinical activity of a ...

A 42-year-old man has become the first person in Indiana to undergo gene therapy for hemophilia B. The therapy aims to ...

We have now extended the study to patients with hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), PTA deficiency (factor XI deficiency) and von Willebrand's disease.

The global hemophilia B treatment market is growing rapidly, powered by gene therapy innovations, extended half-life factor IX products, and an increased concentration on personalized care.

Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral ...

For people with the bleeding disorder hemophilia, life can seem like one continuous state of alertness. If they accidentally ...

Be Biopharma, Inc. ("Be Bio"), a clinical-stage company pioneering engineered B Cell Medicines (BCMs), today announced two key updates at the 66th ASH Annual Meeting in San Diego, CA. These updates ...

The drug is approved for people over age 12 with hemophilia A without factor 8 inhibitors or hemophilia B without factor 9 inhibitors (neutralizing antibodies). Since hemophilia treatment can ...

Informal institutional guidelines restricted the use of factor VIIa (recombinant) to patients with hemophilia A or B with inhibitors, patients with autoimmune antibodies to factor VIII ...

HYMPAVZI is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the European Union (EU) for the treatment of hemophilia A or B and the first hemophilia medicine ...